Tuesday, June 18, 2002 3:18:54 PM
BioShield Develops New Solid Form Antimicrobial - BST 1870 To Be Marketedin the $2 Trillion Worldwide Healthcare Sector
ATLANTA, Jun 18, 2002 /PRNewswire-FirstCall via COMTEX/ -- BioShield Technologies, Inc. (OTC Bulletin Board: BSTI) announced today the development of a new molecular formulation of the trymethoxysilil family in a solid form, high concentrate active ingredient, designed to be used in the healthcare and medical sector.
BioShield Technologies has devoted several years to the development and refining of the new BST 1870. The development of 1870 as a medical-grade solid form antimicrobial/antibacterial has phenomenal potential to be utilized in various medical and healthcare applications and treatments and finally gives BioShield the opportunity to approach the $2 trillion medical industry with this revolutionary new biotechnology. In addition, BST 1870 in solid form also gives BioShield the ability to pursue into markets that do not permit liquid applications, creating entirely new sources of potential revenue and licensee partners
Management stated, "This opens significant potential for BioShield to work with pharmaceutical and biotech companies to take advantage of our core antimicrobial and antibacterial technology. We look forward to unleashing the potential that BST 1870 holds for BioShield and we're extremely excited that we are finally able to approach the healthcare marketplace with a medical- grade product."
The solid form of the BioShield's technology can be added to a wide variety of compounds given the antimicrobial efficacy shown in BioShield other liquid formulations. This new molecule formulation that makes up BST 1870 has no heavy metals, no volatile organic compounds (VOC) and is not regulated by the department of transportation (DOT) as a regulated hazardous material. Research & development of BST 1870 just finished the last toxicological tests showing very low toxicity and no side effects in several different studies conducted by an independent FDA Approved laboratory.
About Bioshield Technologies, Inc.:
BioShield Technologies, Inc., is a Norcross, Georgia-based emerging growth company focused in biotechnology and antimicrobial products. Its core business is committed to the discovery, development, marketing and sale of surface-modifying antimicrobial and biostatic products. The company's antimicrobial technology is a revolutionary alternative to conventional sanitizers, disinfectants, bleaches, biocides or preservatives primarily because it kills bacteria, including HIV, on contact and can remain active for extended time periods. To date BioShield has received three US patents and eight EPA registrations, including the first U.S. germ killer and disinfectant against Salmonella cholerasuis, Staphylococcus aureus and other microorganisms. The company has developed several alliances in different industries, such as healthcare, textiles and storm water.
Further information on BioShield and its line of products can be found by visiting the firm's web site at www.bioshield.com , or by calling 1-770-925-3653, Tim Moses.
Safe Harbor/Forward-looking Statements:
Statements in this news release that are not historical are forward- looking statements. These forward-looking statements are subject to certain risks and uncertainties that could cause actual results to differ materially from those anticipated in any forward-looking statements, all of which are difficult to predict and many of which are beyond the control of the company, including areas such as: developing technologies; dependence on collaborative partners; the inherent complexity and uncertainty regarding the development of products; early-stage development of BioShield; the result of research and development efforts; future capital needs; uncertainty of additional funding; government regulations; and other factors which are detailed in the company's periodic reports and registration statements filed with the Securities and Exchange Commission. BioShield does not undertake to revise or update any forward-looking statement to reflect events or circumstances that may arise after the date hereof. BioShield is a trademark of BioShield Technologies, Inc.
MAKE YOUR OPINION COUNT - Click Here
tbutton.prnewswire.com/prn/11690X86151203
SOURCE BioShield Technologies, Inc.
CONTACT: Tim Moses of BioShield Technologies, Inc., +1-770-925-3653
URL: www.bioshield.com
www.prnewswire.com
Copyright (C) 2002 PR Newswire. All rights reserved.
The best weapon against "fear" is "facts"!!
ATLANTA, Jun 18, 2002 /PRNewswire-FirstCall via COMTEX/ -- BioShield Technologies, Inc. (OTC Bulletin Board: BSTI) announced today the development of a new molecular formulation of the trymethoxysilil family in a solid form, high concentrate active ingredient, designed to be used in the healthcare and medical sector.
BioShield Technologies has devoted several years to the development and refining of the new BST 1870. The development of 1870 as a medical-grade solid form antimicrobial/antibacterial has phenomenal potential to be utilized in various medical and healthcare applications and treatments and finally gives BioShield the opportunity to approach the $2 trillion medical industry with this revolutionary new biotechnology. In addition, BST 1870 in solid form also gives BioShield the ability to pursue into markets that do not permit liquid applications, creating entirely new sources of potential revenue and licensee partners
Management stated, "This opens significant potential for BioShield to work with pharmaceutical and biotech companies to take advantage of our core antimicrobial and antibacterial technology. We look forward to unleashing the potential that BST 1870 holds for BioShield and we're extremely excited that we are finally able to approach the healthcare marketplace with a medical- grade product."
The solid form of the BioShield's technology can be added to a wide variety of compounds given the antimicrobial efficacy shown in BioShield other liquid formulations. This new molecule formulation that makes up BST 1870 has no heavy metals, no volatile organic compounds (VOC) and is not regulated by the department of transportation (DOT) as a regulated hazardous material. Research & development of BST 1870 just finished the last toxicological tests showing very low toxicity and no side effects in several different studies conducted by an independent FDA Approved laboratory.
About Bioshield Technologies, Inc.:
BioShield Technologies, Inc., is a Norcross, Georgia-based emerging growth company focused in biotechnology and antimicrobial products. Its core business is committed to the discovery, development, marketing and sale of surface-modifying antimicrobial and biostatic products. The company's antimicrobial technology is a revolutionary alternative to conventional sanitizers, disinfectants, bleaches, biocides or preservatives primarily because it kills bacteria, including HIV, on contact and can remain active for extended time periods. To date BioShield has received three US patents and eight EPA registrations, including the first U.S. germ killer and disinfectant against Salmonella cholerasuis, Staphylococcus aureus and other microorganisms. The company has developed several alliances in different industries, such as healthcare, textiles and storm water.
Further information on BioShield and its line of products can be found by visiting the firm's web site at www.bioshield.com , or by calling 1-770-925-3653, Tim Moses.
Safe Harbor/Forward-looking Statements:
Statements in this news release that are not historical are forward- looking statements. These forward-looking statements are subject to certain risks and uncertainties that could cause actual results to differ materially from those anticipated in any forward-looking statements, all of which are difficult to predict and many of which are beyond the control of the company, including areas such as: developing technologies; dependence on collaborative partners; the inherent complexity and uncertainty regarding the development of products; early-stage development of BioShield; the result of research and development efforts; future capital needs; uncertainty of additional funding; government regulations; and other factors which are detailed in the company's periodic reports and registration statements filed with the Securities and Exchange Commission. BioShield does not undertake to revise or update any forward-looking statement to reflect events or circumstances that may arise after the date hereof. BioShield is a trademark of BioShield Technologies, Inc.
MAKE YOUR OPINION COUNT - Click Here
tbutton.prnewswire.com/prn/11690X86151203
SOURCE BioShield Technologies, Inc.
CONTACT: Tim Moses of BioShield Technologies, Inc., +1-770-925-3653
URL: www.bioshield.com
www.prnewswire.com
Copyright (C) 2002 PR Newswire. All rights reserved.
The best weapon against "fear" is "facts"!!
The best weapon against "fear" is "facts"!!
Join the InvestorsHub Community
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
